Arcus Biosciences Files 8-K with Shareholder Vote and Financials
Ticker: RCUS · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1724521
Sentiment: neutral
Topics: corporate-governance, financial-reporting, sec-filing
TL;DR
Arcus Biosciences dropped an 8-K on 6/12 detailing shareholder votes and financials.
AI Summary
Arcus Biosciences, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders and other events. The filing includes financial statements and exhibits related to the period ending June 10, 2025. The company is incorporated in Delaware and headquartered in Hayward, California.
Why It Matters
This filing provides an update on corporate governance and financial reporting for Arcus Biosciences, which is crucial for investors to understand the company's operational status and any significant decisions made by shareholders.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate events and financial information, not indicating any immediate operational or financial distress.
Key Numbers
- 001-38419 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-3898435 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Principal Executive Offices
- June 10, 2025 (date) — Earliest event reported
- June 12, 2025 (date) — Filing Date
FAQ
What specific matters were submitted to a vote of Arcus Biosciences' security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What is the significance of the 'Other Events' item reported in this 8-K?
The 'Other Events' item suggests that Arcus Biosciences is disclosing events that are considered material to investors but do not fall under other specific 8-K item categories.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 10, 2025.
What is the primary business of Arcus Biosciences, Inc. based on its SIC code?
Based on its Standard Industrial Classification (SIC) code 2834, Arcus Biosciences, Inc. is primarily involved in the manufacturing of Pharmaceutical Preparations.
Where are Arcus Biosciences, Inc.'s principal executive offices located?
Arcus Biosciences, Inc.'s principal executive offices are located at 3928 Point Eden Way, Hayward, California 94545.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Arcus Biosciences, Inc. (RCUS).